Top Markets
Coin of the day
Tvardi Therapeutics, Inc. Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD
Classement en actions #30251
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Prix de l'action
$1.88
Dernière synchronisation: 2026-08-18
Capitalisation boursière
$17.59M
Changement (1 jour)
0.81%
Changement (1 an)
-92.40%
Pays
US
Échange Tvardi Therapeutics, Inc. (TVRD)

Catégorie

Ratio P/B pour Tvardi Therapeutics, Inc. (TVRD)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Tvardi Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Tvardi Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR